KELOWNA, British Columbia, Dec. 15, 2021 — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) is pleased to announce the signing of a non-exclusive national sales and distribution contract with Trulife Distribution.
Under this agreement, TruLife agrees to distribute, market, and sell Allied’s three brands and products across the United States. These include Tactical Relief™, Equilibrium Bio™, and MaXXa™, all of which are below the 0.3% THC legal limit and are currently sold in the United States.
The agreement will involve national distribution of Allied products into the following distribution channels with TruLife’s existing relationships:
-
Major Online Retailers: TruLife’s expert knowledge of the e-commerce space is a key tool in its distribution strategy and will allow Allied products to be marketed to a national audience, regardless of geographic location.
-
Specialty Health and Nutrition Stores: There are over 25,000 stores that are included in this category which vary widely in size from small, independent shops to large multi-store chains. This includes among others: USA Sports / Muscle Foods, Europa Sports, Complete Nutrition, Vitamin Shoppe, Bulldog Distribution, DNA Distribution, Perfect Nutrition Distributors, Nutrishop, SNI USA, GNC, SOMA Sports, American Fitness Wholesalers, 24-Hour Fitness, Carolinas Sports Nutrition, and Advantis Nutrition.
-
Regional Nutrition Food & Drug Retailers: There are over 50,000 individual retail fronts under this category including both large chains and small, independent shops. This includes among others: Publix, Grocer’s Pride, A&P Stores, Hy-Vee, Schnuck’s, Hannaford, Food Giant, Weis Markets, Marc Glassman, Stater Bros, Big Y Foods, Lewis Drug, London Drugs, H.E.B. Stores, Raley’s, Kinney Drug, Roundy’s, Spartan Stores, Roche Bros, Fresh Market, Ingles, Penn Traffic, Shop n Save, Times Supermarkets, Mac’s Market, BI Mart, Price Chopper, Harris Teeter, ShopRite, Fred Meyer, Giant Eagle, Pathma, Bi-Lo Stores, Duane Reade, Fresh and Easy, Bartell Drug, Fruth Pharmacies, Harmon Stores, Fred’s, Kerr Drug, Wakefern, Wegman’s, Kopp Drug, Bruno’s, Shop Rite, King’s, Piggly Wiggly, and Foodland.
-
National Nutrition Food & Drug Mass Retailers: This category is made up of national food and drug retailers primarily dominated by chains that operate across the United States nationwide. This includes among others: Wal-Mart, Albertson’s, Safeway, CVS, Walgreen’s, Costco, Target, Kroger, BJ’s, Kmart, Sam’s Club, and Rite-Aid.
The partnership paves the way for the rapid entry and expansion of Allied’s presence in the U.S.
“We are excited to be representing Allied’s products in the U.S. health and wellness market,” says TruLife CEO Brian Gould, “Our goal at TruLife is to streamline the experience for brands and consumers, alike. We plan to shepherd Allied’s products along the path to success within the U.S. market.”
The TruLife Distribution team is comprised of top industry leaders in nutritional health and wellness product marketing and distribution. With over 100 years of combined experience, TruLife’s team has established relationships with industry buyers and a proven track record of national distribution to top retail accounts. With sales and marketing experts as well as FDA compliance professionals, Trulife is strategically positioned to successfully distribute Allied’s brands nationally.
“We are very pleased to have received the positive feedback from the TruLife team who has test-marketed the Allied products over the past six months,” says Mr. Calum Hughes, CEO and Chairman of Allied Corp. “The heavy lifting required to get the Allied products into distribution is finally behind us. We have de-risked our supply chain, tested the market, and gained customer feedback from a product development standpoint. It is now time to go national with these products. Trulife is the perfect partner to work with to really scale our sales.”
About TruLife Distribution: TruLife Distribution is owned and operated by Brian Gould. Gould comes from three generations of manufacturing and retail distribution professionals. His self-started company offers a full-service experience that includes sales, marketing, and distribution. Learn more about TruLife Distribution at trulifedist.com.
About Allied Corp: Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the U.S. Federal Government, Allied also has the option to purchase a U.S. cannabis license in the U.S. (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety, and PTSD. Learn more at allied.health.
For more on the Allied Inside™ business model website: CLICK HERE
Investor Relations: mailto:[email protected]
1-877-255-4337
Forward-Looking Statements:
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or the United States (“forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and the introduction of TACTICAL RELIEF™ branded products.
There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company’s continuous disclosure including its Management’s Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company’s profile at www.sec.gov.
Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
